The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Open accessAbstract
The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“evaluated the prognostic relevance of miRNA in patients diagnosed with Luminal breast cancers [150].”
BackgroundThe Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
The hallmarks of cancer: A long non-coding RNA point of view
Gutschner, T., & Diederichs, S. (2012) · RNA Biology · doi:10.4161/rna.20481 · Cited by 1,802
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüuter, C., Galle, J., & Gerdes, J. (1992) · The Journal of Pathology · doi:10.1002/path.1711680404 · Cited by 1,447
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Radiomics: the facts and the challenges of image analysis
Rizzo, S., Botta, F., Raimondi, S., Origgi, D., Fanciullo, C., Morganti, A. G., & Bellomi, M. (2018) · European Radiology Experimental · doi:10.1186/s41747-018-0068-z · Cited by 1,054
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Biomarkers: Potential uses and limitations
Mayeux, R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.182 · Cited by 916
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., Fineberg, S., Flowers, M., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa201 · Cited by 753
Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence
Miller, I., Min, M., Yang, C., Tian, C., Gookin, S., Carter, D., & Spencer, S. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.110 · Cited by 647
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2560-8 · Cited by 601
An International Ki67 Reproducibility Study
Polley, M.-Y. C., Leung, S. C. Y., McShane, L. M., Gao, D., Hugh, J. C., Mastropasqua, M. G., Viale, G., Zabaglo, L. A., Penault-Llorca, F., Bartlett, J. M. S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt306 · Cited by 595
Prat, A., Cheang, M. C. U., Martín, M., Parker, J. S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P. S., Nielsen, T. O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4134 · Cited by 587
Hammond, M. E. H., Hayes, D. F., Wolff, A. C., Mangu, P. B., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.777003 · Cited by 583
Ki-67 acts as a biological surfactant to disperse mitotic chromosomes
Cuylen, S., Blaukopf, C., Politi, A. Z., Müller-Reichert, T., Neumann, B., Poser, I., Ellenberg, J., Hyman, A. A., & Gerlich, D. W. (2016) · Nature · doi:10.1038/nature18610 · Cited by 562
Muenst, S., Schaerli, A. R., Gao, F., Däster, S., Trella, E., Droeser, R. A., Muraro, M. G., Zajac, P., Zanetti, R., Gillanders, W. E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2988-5 · Cited by 558
Hammond, M. E. H., Hayes, D. F., Dowsett, M., et al. (2010) · PubMed Central · Cited by 541
Regression of murine lung tumors by the let-7 microRNA
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhaas, J. B., et al. (2010) · Oncogene · doi:10.1038/onc.2009.445 · Cited by 500
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4501 · Cited by 369
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.951s.11.2 · Cited by 348
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Fasching, P. A., Heusinger, K., Haeberle, L., Niklos, M., Hein, A., Bayer, C. M., Rauh, C., Schulz-Wendtland, R., Bani, M. R., Schrauder, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-486 · Cited by 328
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Hamam, R., Hamam, D., Alsaleh, K. A., Kassem, M., Zaher, W., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.440 · Cited by 322
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Jones, R. L., Salter, J., A’Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., Smith, I. E., & Dowsett, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0081-7 · Cited by 321
Luporsi, E., André, F., Spyratos, F., Martin, P.-M., Jacquemier, J., Penault-Llorca, F., Tubiana-Mathieu, N., Sigal-Zafrani, B., Arnould, L., Gompel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1837-z · Cited by 320
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3559-0 · Cited by 286
Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors
Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T., & Snyderwine, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn275 · Cited by 224
An international study to increase concordance in Ki67 scoring
Polley, M.-Y. C., Leung, S. C. Y., Gao, D., Mastropasqua, M. G., Zabaglo, L. A., Bartlett, J. M. S., McShane, L. M., Enos, R. A., Badve, S. S., Bane, A. L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.38 · Cited by 214
Mengel, M., von Wasielewski, R., Wiese, B., Rüdiger, T., Müller‐Hermelink, H. K., & Kreipe, H. (2002) · The Journal of Pathology · doi:10.1002/path.1218 · Cited by 213
Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-57 · Cited by 211
Ellis, M. J., Coop, A., Singh, B., Yu, T., Llombart‐Cussac, A., Jänicke, F., Mauriac, L., Quebe‐Fehling, E., Chaudri‐Ross, H. A., Evans, D. B., et al. (2003) · PubMed · Cited by 202
The rise of the genome and personalised medicine
Brittain, H. K., Scott, R., & Thomas, E. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-6-545 · Cited by 201
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Elizabeth, A., & Inoue, K. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4773 · Cited by 196
PD-1/PD-L1 Pathway in Breast Cancer
Schütz, F., Stefanovic, S., Mayer, L., von Au, A., Domschke, C., & Sohn, C. (2017) · Oncology Research and Treatment · doi:10.1159/000464353 · Cited by 196
Regulation of let-7 and its target oncogenes (Review)
WANG, X., CAO, L., WANG, Y., WANG, X., LIU, N., & YOU, Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.609 · Cited by 193
Ki-67 expression during rat liver regeneration after partial hepatectomy
Gerlach, C., Sakkab, D. Y., Scholzen, T. E., Daβler, R., Alison, M. R., & Gerdes, J. (1997) · Hepatology · doi:10.1002/hep.510260307 · Cited by 186
Digital image analysis outperforms manual biomarker assessment in breast cancer
Stålhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N. P., Mølholm, I., Kis, L., Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.34 · Cited by 186
The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
Zhu, X., Chen, L., Huang, B., Wang, Y., Ji, L., Wu, J., Di, G., Liu, G., Yu, K., Shao, Z., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57094-3 · Cited by 178
Strategies for developing Ki67 as a useful biomarker in breast cancer
Denkert, C., Budczies, J., von Minckwitz, G., Wienert, S., Loibl, S., & Klauschen, F. (2015) · The Breast · doi:10.1016/j.breast.2015.07.017 · Cited by 177
Ghebeh, H., Tulbah, A. M., Mohammed, S. F., Elkum, N. B., Amer, S. M. B., Al‐Tweigeri, T., & Dermime, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22703 · Cited by 171
Klöppel, G., & La Rosa, S. (2018) · Virchows Archiv · doi:10.1007/s00428-017-2258-0 · Cited by 171
Gnant, M., Harbeck, N., & Thomssen, C. (2017) · Breast Care · doi:10.1159/000475698 · Cited by 155
Chromophore‐assisted light inactivation of pKi‐67 leads to inhibition of ribosomal RNA synthesis
Rahmanzadeh, R., Hüttmann, G., Gerdes, J., & Scholzen, T. E. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00433.x · Cited by 153
Leung, S. C. Y., Nielsen, T. O., Zabaglo, L. A., Arun, I., Badve, S., Bane, A. L., Bartlett, J. M. S., Borgquist, S., Chang, M. C., Dodson, A. R., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.14 · Cited by 153
Tian, S., Roepman, P., Veer, L. J. V., Bernards, R., Snoo, F. D., & Glas, A. M. (2010) · Biomarker Insights · doi:10.4137/bmi.s6184 · Cited by 143
Li, Y., He, M., Zhou, Y., Yang, C., Wei, S., Bian, X., Christopher, O., & Xie, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00139 · Cited by 131
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Kim, K. I., Lee, K. H., Kim, T. R., Chun, Y. S., Lee, T. H., & Park, H. K. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.1.40 · Cited by 129
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
Sheri, A., Smith, I. E., Johnston, S. R. D., A’Hern, R., Nerurkar, A. Y., Jones, R. L., Hills, M., DETRE, S. I., Pinder, S. E., Symmans, W. F., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu508 · Cited by 125
Carlomagno, N., Incollingo, P., Tammaro, V., Peluso, G., Rupealta, N., Chiacchio, G., Sotelo, M. L. S., Minieri, G., Pisani, A., Riccio, E., et al. (2017) · BioMed Research International · doi:10.1155/2017/7869802 · Cited by 118
Schonk, D., Kuijpers, H. J. H., van Drunen, E., van Dalen, C. H., van Kessel, A. H. M. G., Verheijen, R., & Ramaekers, F. C. S. (1989) · Human Genetics · doi:10.1007/bf00285178 · Cited by 116
McVeigh, T. P., & Kerin, M. J. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s109847 · Cited by 115
Self-citationBrown, J. R., DiGiovanna, M. P., Killelea, B. K., Lannin, D. R., & Rimm, D. L. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.128 · Cited by 112
Breast Cancer in the Personal Genomics Era
Ellsworth, R. E., Decewicz, D. J., Shriver, C. D., & Ellsworth, D. L. (2010) · Current Genomics · doi:10.2174/138920210791110951 · Cited by 108
Klauschen, F., Wienert, S., Schmitt, W., Loibl, S., Gerber, B., Blohmer, J., Huober, J., Rüdiger, T., Erbstößer, E., Mehta, K. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1283 · Cited by 103
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
Niu, G., Sun, X., Cao, Q., Courter, D. L., Koong, A. C., Le, Q., Gambhir, S. S., & Chen, X. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2495 · Cited by 100
Predicting Clinical Outcomes Using Molecular Biomarkers
Burke, H. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s33380 · Cited by 100
Bae, S. B., Cho, H. D., Oh, M., Lee, J.-H., Jang, S.-H., Hong, S. A., Cho, J., Kim, S. Y., Han, S. W., Lee, J. E., et al. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.3.242 · Cited by 98
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Pabla, S., Conroy, J. M., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Hagen, J., Giamo, V., Andreas, J., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0506-3 · Cited by 95
Yu, K., Wu, J., Shen, Z., & Shao, Z. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2423 · Cited by 91
Stemmer, S. M., Steiner, M., Rizel, S., Geffen, D. B., Nisenbaum, B., Peretz, T., Soussan‐Gutman, L., Bareket‐Samish, A., Isaacs, K., Rosengarten, O. S., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0033-7 · Cited by 85
Immunotherapy in breast cancer
Bayraktar, S., Batoo, S. A., Okuno, S. H., & Glück, S. (2019) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_2_19 · Cited by 84
Abubakar, M., Orr, N., Daley, F. M., Coulson, P., Ali, H. R., Blows, F. M., Benitez, J. J., Milne, R. L., Brenner, H., Stegmaier, C., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0765-6 · Cited by 83
Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
Wu, Q., Ma, G., Deng, Y., Luo, W., Zhao, Y., Li, W., & Zhou, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01068 · Cited by 83
Falck, A., Fernö, M., Bendahl, P., & Rydén, L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-558 · Cited by 76
Munzone, E., Botteri, E., Sciandivasci, A., Curigliano, G., Nolè, F., Mastropasqua, M. G., Rotmensz, N., Colleoni, M. A., Esposito, A., Adamoli, L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2040-6 · Cited by 70
Hooghe, B., Hulpiau, P., Roy, F. M. V., & Bleser, P. D. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn195 · Cited by 70
Zhong, F., Bi, R., Yu, B., Yang, F., Yang, W., & Shui, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150505 · Cited by 67
Ki-67 is a reliable pathological grading marker for neuroendocrine tumors
Nadler, A., Cukier, M., Rowsell, C. H., Kamali, S., Feinberg, Y., Singh, S., & Law, C. H. L. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1410-8 · Cited by 66
Muftah, A. A., Aleskandarany, M. A., Al-kaabi, M. M., Sonbul, S. N., Diez, M., Nolan, C. C., Caldas, C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4270-0 · Cited by 63
Breast cancer Ki-67 expression prediction by digital breast tomosynthesis radiomics features
Tagliafico, A. S., Bignotti, B., Rossi, F., de Matos, J. F. R. G., Calabrese, M., Valdora, F., & Houssami, N. (2019) · European Radiology Experimental · doi:10.1186/s41747-019-0117-2 · Cited by 63
Faratian, D., Munro, A. F., Twelves, C., & Bartlett, J. M. S. (2009) · Histopathology · doi:10.1111/j.1365-2559.2008.03191.x · Cited by 61
Truong, P. T., Bernstein, V., Wai, E. S., Chua, B. H., Speers, C. H., & Olivotto, I. A. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02973-5 · Cited by 57
Thakur, S. S., Li, H., Chan, A. M. Y., Tudor, R., Bigras, G., Morris, D. G., Enwere, E. K., & Yang, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0188983 · Cited by 55
A new tool for technical standardization of the Ki67 immunohistochemical assay
Aung, T. N., Ács, B., Warrell, J., Bai, Y., Gaule, P., Martínez-Morilla, S., Vathiotis, I. A., Shafi, S., Moutafi, M. K., Gerstein, M., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00745-6 · Cited by 52
Riber‐Hansen, R., Vainer, B., & Steiniche, T. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02854.x · Cited by 51
Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas
Sørbye, S. W., Kilvaer, T. K., Valkov, A., Dønnem, T., Smeland, E., Al-Shibli, K. I., Bremnes, R. M., & Busund, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047068 · Cited by 50
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 48
Correlation between DCE‑MRI radiomics features and Ki‑67 expression in invasive breast cancer
Juan, M., Ji, Y., Peng, G., Jun, L., Feng, S., & Fang, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9271 · Cited by 46
Zhu, L., Sun, J., Wang, L., Li, Z., Wang, L., & Li, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00962 · Cited by 46
On the concept of objectivity in digital image analysis in pathology
Tadrous, P. J. (2010) · Pathology · doi:10.3109/00313021003641758 · Cited by 44
The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment
Davey, M. G., Davies, M., Lowery, A., Miller, N., & Kerin, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158290 · Cited by 44
Self-citationSopik, V., Sun, P., & Narod, S. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4333-2 · Cited by 43
Application of Radiomics for Personalized Treatment of Cancer Patients
Meng, Y., Sun, J. Y., Qu, N., Zhang, G., Yu, T., & Piao, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s232473 · Cited by 43
Mitchell, K. G., Parra, E. R., Nelson, D. B., Zhang, J., Wistuba, I. I., Fujimoto, J., Roth, J. A., Antonoff, M. B., Corsini, E. M., Vaporciyan, A. A., et al. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.04.084 · Cited by 34
Davey, M. G., Kerin, E. P., O'Flaherty, C., Maher, E., Richard, V., McAnena, P. F., McLaughlin, R. P., Sweeney, K., Barry, M. K., Malone, C. M., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.06.005 · Cited by 31
Self-citationWang, R.-X., Chen, S., Jin, X., & Shao, Z. (2016) · Scientific Reports · doi:10.1038/srep30091 · Cited by 30
The future of clinical cancer genomics
Offit, K. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.002 · Cited by 28
Davey, M. G., Ryan, É. J., Folan, P., O’Halloran, N., Boland, M. R., Barry, M. K., Sweeney, K. J., Malone, C., McLaughlin, R., Kerin, M. J., et al. (2021) · BJS Open · doi:10.1093/bjsopen/zrab040 · Cited by 28
Self-citationDavey, M. G., Ryan, É. J., Elwahab, S. M. A., Elliott, J. A., McAnena, P. F., Sweeney, K., Malone, C. M., McLaughlin, R. P., Barry, M. K., Keane, M., et al. (2021) · The Breast Journal · doi:10.1111/tbj.14217 · Cited by 26
Self-citationDavey, M. G., Ryan, É. J., McAnena, P. F., Boland, M. R., Barry, M. K., Sweeney, K. J., Malone, C., McLaughlin, R., Lowery, A., & Kerin, M. J. (2021) · Surgical Oncology · doi:10.1016/j.suronc.2021.101531 · Cited by 25
Self-citationDavey, M. G., Ryan, É. J., Davey, M. S., Lowery, A., Miller, N., & Kerin, M. J. (2021) · British journal of surgery · doi:10.1093/bjs/znab103 · Cited by 24
Self-citationIdentifying Ki-67 specific miRNA–mRNA interactions in malignant astrocytomas
Liu, Y., Tang, K., Yan, W., Wang, Y., You, G., Kang, C., Jiang, T., & Zhang, W. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.04.030 · Cited by 22
Sakurai, M., Masuda, M., Miki, Y., Hirakawa, H., Suzuki, T., & Sasano, H. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000141 · Cited by 21
Ekholm, M., Beglerbegovic, S., Grabau, D. A., Lövgren, K., Malmström, P., Hartman, L. W., & Fernö, M. (2014) · Histopathology · doi:10.1111/his.12392 · Cited by 17
Ma, J., Chi, D., Wang, Y., Yan, Y., Zhao, S., Liu, H., Jing, J., Pu, H., & Zhang, M. (2018) · Journal of Cancer · doi:10.7150/jca.26155 · Cited by 15
Yun, S., Park, Y., Moon, S., Ahn, S., Lee, K., Park, H. J., Lee, H. S., Choe, G., & Lee, K. S. (2019) · Journal of Cancer · doi:10.7150/jca.30573 · Cited by 15
A histopathological tool for quantification of biomarkers with sub-cellular resolution
Kårsnäs, A., Strand, R., Doré, J., Ebstrup, T., Lippert, M. F., & Bjerrum, K. (2014) · Computer Methods in Biomechanics and Biomedical Engineering Imaging & Visualization · doi:10.1080/21681163.2014.885120 · Cited by 8
Metadata
- Authors
- Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-09-03
- Volume
- 13
- Issue
- 17
- Pages
- 4455
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3197162231
- Cited by
- 298
- References
- 124
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.